Supernus Pharmaceuticals Balance Sheet
NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Supernus Pharmaceuticals financial position
At the end of fiscal 2025, Supernus Pharmaceuticals reported total assets of $1.45 billion, up 6.2% from a year earlier against total liabilities of $390.9 million. Shareholders' equity stood at $1.06 billion, or 73.1% of assets. The company held $128.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 1.90, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Supernus Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 128.45M | 69.33M | 75.05M | 93.12M | 203.43M | 288.64M | 181.38M | 192.25M | 100.30M | 66.40M |
| Short-Term Investments | — | — | — | 368.21M | 136.25M | 133.89M | 165.69M | 163.77M | 39.74M | 23.72M |
| Receivables | 187.80M | 142.08M | 144.16M | 165.50M | 148.93M | 140.88M | 87.33M | 102.92M | 65.59M | 41.53M |
| Inventory | 112.48M | 54.29M | 77.41M | 91.54M | 85.96M | 48.33M | 26.63M | 25.66M | 16.30M | 16.80M |
| Total Current Assets | 644.18M | 686.07M | 493.11M | 734.15M | 601.59M | 630.42M | 472.64M | 493.49M | 228.45M | 151.40M |
| Property, Plant & Equipment | 10.53M | 11.54M | 13.53M | 15.17M | 16.95M | 37.82M | 17.07M | 4.09M | 5.12M | 4.34M |
| Goodwill | 124.88M | 117.02M | 117.02M | 117.02M | 117.52M | 77.91M | 0 | — | — | — |
| Intangible Assets | 569.46M | 521.91M | 599.89M | 702.46M | 784.69M | 364.34M | 24.84M | 31.37M | 36.02M | 36.35M |
| Long-Term Investments | — | — | — | 93.90M | 119.17M | 350.36M | 591.77M | 418.80M | 133.64M | 75.41M |
| Total Assets | 1.45B | 1.37B | 1.28B | 1.70B | 1.69B | 1.50B | 1.16B | 977.81M | 424.46M | 309.57M |
| Accounts Payable | 2.68M | 4.59M | 1.96M | 10.54M | 9.33M | 6.15M | 10.14M | 3.19M | 6.84M | 8.05M |
| Short-Term Debt | — | — | — | — | 0 | — | — | — | — | — |
| Total Current Liabilities | 338.17M | 292.40M | 290.20M | 687.96M | 315.38M | 245.11M | 160.59M | 161.35M | 123.00M | 80.74M |
| Long-Term Debt | — | — | — | — | 379.25M | — | — | — | — | — |
| Total Liabilities | 390.93M | 332.34M | 356.16M | 816.30M | 873.30M | 759.24M | 564.85M | 524.79M | 156.98M | 117.81M |
| Shareholders' Equity | 1.06B | 1.04B | 921.52M | 886.20M | 815.85M | 744.86M | 595.43M | 453.02M | 267.48M | 191.75M |
| Retained Earnings | 517.88M | 556.43M | 482.56M | 481.25M | 379.92M | 326.50M | 199.55M | 86.49M | -26.82M | -84.29M |
| Total Debt | — | — | — | — | 379.25M | — | — | — | — | — |
| Net Cash (Debt) | 128.45M | 69.33M | 75.05M | 461.33M | -39.57M | 422.53M | 347.07M | 356.02M | 140.04M | 90.12M |
| Shares Outstanding | 57.46M | 55.74M | 54.72M | 54.25M | 53.26M | 52.87M | 52.53M | 52.32M | 51.31M | 49.97M |
This table shows 10 annual periods of Supernus Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow SUPN's reporting calendar. What is a balance sheet?